Chinese biotech faces reality check as ArriVent drug failure sinks stock in US
- Posted on October 7, 2026
- By South China Morning Post
- 0 Views
- 1 min read
In brief
Generating AI summary…
Chinese biotech faces reality check as ArriVent drug failure sinks stock in US
US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.
